Final Contrast Imaging Guidance Addresses Some, Not All, Industry Critiques
This article was originally published in The Gray Sheet
Executive Summary
FDA's final guidance on the intersecting regulatory pathways of imaging devices and contrast agents clarifies which marketing submissions are needed for various product changes, but still does not address data requirements for specific indications, such as breast cancer imaging